RxDoctor Payments Data

Farah Burhani, MD

Hospitalist · Sugar Land, TXNPI 1851788020

Payments from drug & device makers

$1,422in general payments, 2019–2025

Across 45 payments — averaging $31.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$652
  • Pfizer$339
  • Genentech USA, Inc.$125
  • AbbVie$116
  • Boehringer Ingelheim$98
  • Amgen$28
  • plus $65 from 3 others

What the payments were for

  • Food & beverage$1,422100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,422 in reported general payments places this provider in the 90th percentile of 1,284 hospitalist providers in Texas.

See all hospitalist providers in Texas

Medicare billing

Part B allowed, 2024
$91,685
Medicare patients
352
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban21$12,084
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,009
Nifedipine ErNifedipine25$452
Cefdinir36$380
Pantoprazole Sodium44$312
Ondansetron OdtOndansetron23$298
Nitroglycerin11$281
ClopidogrelClopidogrel Bisulfate21$260
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen43$256
Metronidazole20$198
Metoprolol Succinate23$195
Amiodarone Hcl19$152
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$119
Ciprofloxacin Hcl17$115
Metoprolol Tartrate29$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$339$12,08421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 hospitalist providers in Texas.

Other hospitalist in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →